Loading
A phase 3 trial of Dabrafenib, Trametinib in thyroid cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer is a phase 3 interventional study registered as NCT04940052 by Novartis Pharmaceuticals, with 153 participants enrolled, started 2021-11-15 and due to reach its primary completion in 2025-01-22. Interventions recorded: Dabrafenib, Trametinib, Trametinib Placebo, Dabrafenib placebo. Conditions listed: Differentiated Thyroid Cancer (DTC). Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
153 enrolled.
95% CI 10.2 to 21.2; Figures from the ClinicalTrials.gov results section (first posted 2026-05-22), not from a publication · 95% CI 2.3 to 7.5
Source95% CI 47.2 to 67.2; Figures from the ClinicalTrials.gov results section (first posted 2026-05-22), not from a publication · 95% CI 0.5 to 13.2
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS)primary | Dabrafenib Plus Trametinib | 101 | 12.8 months | 0.38 (0.25 to 0.57) | <0.001 | link |
| Dabrafenib Placebo Plus Trametinib Placebo | 52 | 3.7 months | ||||
| Overall Response Rate (ORR) | Dabrafenib Plus Trametinib | 101 | 57.4% | - | <0.001 | link |
| Dabrafenib Placebo Plus Trametinib Placebo | 52 | 3.8% |
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib, Novartis, Small-molecule kinase inhibitors.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.